Eiger Biopharmaceuticals, Inc.

Leland Stanford Junior University

Anthera Pharmaceuticals, Inc.

Amylyx Pharmaceuticals Inc.

Debra Odink

Colleen M Craig

Tracey L McLaughlin

Xiaofeng Xiong

Christine M N Smith

Patrick Irving Eacho

Scott Chadwick

Joaquim Trias

Bernadine Fraser

Kenneth Gould

Marian Mosior

Colin Hislop

Paul Truex

Christine MN Smith

Provided herein are liquid pharmaceutical formulations comprising exendin (9-39) or a pharmaceutically acceptable salt thereof and a tonicity modifier in a physiologically acceptable buffer having a pH in the range of about 5 to about 6. In some embodiments, the buffered liquid formulation comprises exendin (9-39) or a pharmaceutically acceptable salt thereof in an acetate buffer or a citrate buffer. Methods of treating or preventing hyperinsulinemic hypoglycemia in a subject comprising administering to the subject the buffered liquid formulation are also provided.

Methods of using buffered formulations of exendin (9-39)

Buffered formulations of exendin (9-39)

Administration of sPLAinhibitors has been found to decrease cholesterol levels, atherosclerotic plaque formation and aortic aneurysm in mice, and to decrease cholesterol and triglyceride levels in humans. Interestingly, administration of sPLAinhibitors was found to decrease cholesterol levels even when the inhibitors were administered only once per day. Therefore, provided herein are methods of treating dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome, by administering one or more sPLAinhibitors. Significantly, administration of sPLAinhibitors and various compounds used in the treatment of CVD, such as for example statins, resulted in greater decreases in LDL and LDL particle levels in a synergistic manner. In addition, administration of sPLAinhibitors and statins resulted in a synergistic decrease in plaque content. Therefore, also provided herein are compositions comprising one or more sPLAinhibitors and one or more compounds used in the treatment of CVD, such as for example statins, and methods of using these compositions to treat dyslipidemia, CVD, and conditions associated with CVD such as atherosclerosis and metabolic syndrome.

[object Object]

Growing community of inventors

Oakland, CA, United States of America

Debra Odink